Citation Impact
Citing Papers
In Vivo Electroporation Enhances the Immunogenicity of Hepatitis C Virus Nonstructural 3/4A DNA by Increased Local DNA Uptake, Protein Expression, Inflammation, and Infiltration of CD3+ T Cells
2007
Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection
2016
Emerging therapies for the treatment of hepatitis C
2013 StandoutNobel
Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus
2008
Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies
2018 StandoutNobel
The Spring α-Helix Coordinates Multiple Modes of HCV (Hepatitis C Virus) NS3 Helicase Action
2016 StandoutNobel
Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors
2010
Old and emerging therapies in chronic hepatitis C: an update
2007
Nonstructural protein 3‐4A: the Swiss army knife of hepatitis C virus
2011
Hepatitis C virus resistance to protease inhibitors
2011
Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs)
2009
Recapitulation of the hepatitis C virus life-cycle in engineered murine cell lines
2013 StandoutNobel
Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: A phase 1b multiple ascending dose study
2010
Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical Trials
2013
Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir
2011
Multi-input chemical control of protein dimerization for programming graded cellular responses
2019 StandoutNobel
Mechanism of Activation of PSI-7851 and Its Diastereoisomer PSI-7977
2010
A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C
2012
The cyclophilin inhibitor Debio-025 shows potent anti–hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus
2008
Management of Hepatic Complications in HIV‐Infected Persons
2008
The importance of resistance to direct antiviral drugs in HCV infection in clinical practice
2015
Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses
2010 StandoutNobel
Temporal Proteome and Lipidome Profiles Reveal Hepatitis C Virus-Associated Reprogramming of Hepatocellular Metabolism and Bioenergetics
2010 StandoutNobel
Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191)
2011
Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir
2016 StandoutNobel
The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors
2012
Practical evaluation of a mouse with chimeric human liver model for hepatitis C virus infection using an NS3-4A protease inhibitor
2010
The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C
2011
Perspectives and challenges of interferon-free therapy for chronic hepatitis C
2012
Antiviral Suppression vs Restoration of RIG-I Signaling by Hepatitis C Protease and Polymerase Inhibitors
2008
Natural products to drugs: natural product-derived compounds in clinical trials
2008 Standout
Interferon-based therapy for chronic hepatitis C: current and future perspectives
2008
Treating viral hepatitis C: efficacy, side effects, and complications
2006
Physiological stress in ecology: lessons from biomedical research
2004 Standout
Modulation of host metabolism as a target of new antivirals
2007
Telaprevir Alone or With Peginterferon and Ribavirin Reduces HCV RNA in Patients With Chronic Genotype 2 but Not Genotype 3 Infections
2011
Cyclophilin inhibitors in hepatitis C viral infection
2007
Sofosbuvir Inhibits Hepatitis E Virus Replication In Vitro and Results in an Additive Effect When Combined With Ribavirin
2015 StandoutNobel
The ins and outs of hepatitis C virus entry and assembly
2013 StandoutNobel
Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus
2011
Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection
2009
Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice
2010
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
2009 StandoutNature
Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection
2009
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
2020 Standout
Crystal Structure of the HCV IRES Central Domain Reveals Strategy for Start-Codon Positioning
2011 StandoutNobel
Expression of heterologous proteins flanked by NS3-4A cleavage sites within the hepatitis C virus polyprotein
2013 StandoutNobel
New NS5B polymerase inhibitors for hepatitis C
2010
Protease and polymerase inhibitors for the treatment of hepatitis C
2009
Resistance mechanisms in HCV: from evolution to intervention
2008
A reporter cell line for rapid and sensitive evaluation of hepatitis C virus infectivity and replication
2009
SCH 503034, a Novel Hepatitis C Virus Protease Inhibitor, Plus Pegylated Interferon α-2b for Genotype 1 Nonresponders
2007
A Functional Genomic Screen Identifies Cellular Cofactors of Hepatitis C Virus Replication
2009
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
2014 Standout
Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1
2010
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
2013 StandoutNobel
A Hepatitis C Virus (HCV) Vaccine Comprising Envelope Glycoproteins gpE1/gpE2 Derived from a Single Isolate Elicits Broad Cross-Genotype Neutralizing Antibodies in Humans
2013 StandoutNobel
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
2008 Standout
Curing a viral infection by targeting the host: The example of cyclophilin inhibitors
2013
Antiretroviral Treatment of Adult HIV Infection
2012 Standout
Albinterferon α-2b: a genetic fusion protein for the treatment of chronic hepatitis C
2007
Adrenocortical Function in a New World Primate, the Marmoset Monkey, Callithrix jacchus
2000
Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection
2009
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
2011 Standout
The way forward in HCV treatment — finding the right path
2007 StandoutNobel
Innate Immune Responses to Hepatitis C Virus
2013 StandoutNobel
Review article: specifically targeted anti‐viral therapy for hepatitis C – a new era in therapy
2010
Telaprevir and pegylated interferon–alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients
2007
Helicase Inhibitors as Specifically Targeted Antiviral Therapy for Hepatitis c
2009
Hepatitis C virus infects rhesus macaque hepatocytes and simianized mice
2015 StandoutNobel
The HCV IRES pseudoknot positions the initiation codon on the 40S ribosomal subunit
2010 StandoutNobel
Broadly Neutralizing Immune Responses against Hepatitis C Virus Induced by Vectored Measles Viruses and a Recombinant Envelope Protein Booster
2012 StandoutNobel
Modeling hepatitis C virus infection using human induced pluripotent stem cells
2012 StandoutNobel
Efficient Replication of Genotype 3a and 4a Hepatitis C Virus Replicons in Human Hepatoma Cells
2012 StandoutNobel
Visualization of Positive and Negative Sense Viral RNA for Probing the Mechanism of Direct-Acting Antivirals against Hepatitis C Virus
2019 StandoutNobel
Development of an Intergenotypic Hepatitis C Virus (HCV) Cell Culture Method To Assess Antiviral Susceptibilities and Resistance Development of HCV NS3 Protease Genes from HCV Genotypes 1 to 6
2010
Selected Replicon Variants with Low-Level In Vitro Resistance to the Hepatitis C Virus NS5B Polymerase Inhibitor PSI-6130 Lack Cross-Resistance with R1479
2008
Seed Sequence-Matched Controls Reveal Limitations of Small Interfering RNA Knockdown in Functional and Structural Studies of Hepatitis C Virus NS5A-MOBKL1B Interaction
2014 StandoutNobel
Antisense Gets a Grip on miR-122 in Chimpanzees
2010 StandoutNobel
Development of a multiplex phenotypic cell-based high throughput screening assay to identify novel hepatitis C virus antivirals
2013 StandoutNobel
The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors
2008
Update of the Belgian Association for the Study of the Liver guidelines for the treatment of chronic hepatitis C genotype 1 with protease inhibitors.
2012
Fast Hepatitis C Virus RNA Elimination and NS5A Redistribution by NS5A Inhibitors Studied by a Multiplex Assay Approach
2015 StandoutNobel
Relative Replication Capacity and Selective Advantage Profiles of Protease Inhibitor-Resistant Hepatitis C Virus (HCV) NS3 Protease Mutants in the HCV Genotype 1b Replicon System
2007
Response of Hepatitis C Virus to Long-Term Passage in the Presence of Alpha Interferon: Multiple Mutations and a Common Phenotype
2013 StandoutNobel
Viral Determinants of Resistance to Treatment in Patients with Hepatitis C
2007
EASL Recommendations on Treatment of Hepatitis C 2018
2018 Standout
Increased Replicative Fitness Can Lead to Decreased Drug Sensitivity of Hepatitis C Virus
2014 StandoutNobel
Replicons of a Rodent Hepatitis C Model Virus Permit Selection of Highly Permissive Cells
2019 StandoutNobel
A cell protection screen reveals potent inhibitors of multiple stages of the hepatitis C virus life cycle
2010 StandoutNobel
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Development of novel treatments for hepatitis C
2009
A Host of Factors Regulating Influenza Virus Replication
2010 StandoutNobel
Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents
2014 StandoutNobel
Molecular Mechanism of Hepatitis C Virus Replicon Variants with Reduced Susceptibility to a Benzofuran Inhibitor, HCV-796
2008
Towards a small animal model for hepatitis C
2009 StandoutNobel
Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells
2013 StandoutNobel
Internal Disequilibria and Phenotypic Diversification during Replication of Hepatitis C Virus in a Noncoevolving Cellular Environment
2017 StandoutNobel
Hepatitis C Virus Genotype 5a Subgenomic Replicons for Evaluation of Direct-Acting Antiviral Agents
2014 StandoutNobel
Single‐molecule imaging reveals the translocation and DNA looping dynamics of hepatitis C virus NS3 helicase
2017 StandoutNobel
Barrier-Independent, Fitness-Associated Differences in Sofosbuvir Efficacy against Hepatitis C Virus
2016 StandoutNobel
Detailed Computational Study of the Active Site of the Hepatitis C Viral RNA Polymerase to Aid Novel Drug Design
2013 StandoutNobel
Role of Scavenger Receptor Class B Type I in Hepatitis C Virus Entry: Kinetics and Molecular Determinants
2009 StandoutNobel
Works of Susan Purdy being referenced
Inhibition of corticosteroid production by sodium pentobarbitone in rat adrenocortical preparations
1993
Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C
2007
Stimulation of steroidogenesis by forskolin in rat adrenal zona glomerulosa cell preparations
1991
Rapid Decline of Viral RNA in Hepatitis C Patients Treated With VX-950: A Phase Ib, Placebo-Controlled, Randomized Study
2006
Phase 2 study of the combination of merimepodib with peginterferon-α2b, and ribavirin in nonresponders to previous therapy for chronic hepatitis C
2007
737 Initial results of a 14-day study of the hepatitis C virus inhibitor protease VX-950, in combination with peginterferon-alpha-2a
2006
12 Wild-type HCV NS3 protease re-emerges during follow-up after 14 days of dosing with VX-950 in patients with genotype 1 HCV
2006